I think that the very existence of RCE 529, suggests that is exactly what they are doing.
Instead of trying to make RCE 327 a drug "for everything"; create a variant that can be targeted to specific outcomes.
I still believe the main effort is focused on the root chemistry at play, namely, the unique modus operandi of RCE 327, which will inherently benefit the other variants, without disrupting the direct progress of bringing 327 to the market to fight Sepsis.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)